2021 ASCO Virtual Annual Meeting*

Download All
June 4-8, 2021; Online at https://conferences.asco.org/am
Review slidesets and expert analyses of key data from the 2021 Clinical Oncology Virtual Scientific Meeting!

Gastrointestinal Cancers

Capsule Summary Slidesets

In the final analysis from KEYNOTE-177, first-line pembrolizumab was associated with an improved median OS compared with chemotherapy in patients with MSI-H/dMMR mCRC.

Released: June 17, 2021

In previously untreated patients with advanced gastroesophageal cancers, nivolumab plus chemotherapy significantly prolonged OS and PFS vs chemotherapy alone.

Released: June 10, 2021

Compared with placebo, adjuvant nivolumab significantly prolonged disease-free survival in patients with resected EC/GEJC who had received neoadjuvant chemotherapy.

Released: June 17, 2021

Interim analysis of the KEYNOTE-811 trial shows significantly higher response rate and more durable responses with pembrolizumab added to first-line trastuzumab and chemotherapy in gastric or gastroesophageal junction cancer.

Released: June 17, 2021

In patients with advanced esophageal cancer and no previous therapy for advanced disease, nivolumab with either ipilimumab or chemotherapy significantly increased overall survival vs chemotherapy alone.

Released: June 11, 2021
Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by an educational grant from
Merck Sharp & Dohme Corp.

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.


Cookie Settings